SEC Form 4 · accession 0001140361-19-004271
Opus Genetics, Inc. · IRD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lara Sullivan
Director
Period of report
Feb 27, 2019
Accepted (ET)
Mar 1, 2019 · 5:31 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001228627
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $0.53 | Feb 27, 2019 | A | 84,968 | A | — | Feb 27, 2019 | Common Stock | 84,968 | 84,968 | D |
Explanation of responses
- F1Options will vest and become exercisable based on the following schedule: 28,322 on February 27, 2020, 28,323 on February 27, 2021, and 28,323 on February 27, 2022.